Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 1;145(2):153-158.
doi: 10.1001/jamaoto.2018.3650.

Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Brianna N Harris  1 , Patrik Pipkorn  2 , Ky Nam Bai Nguyen  3 , Ryan S Jackson  2 , Shyam Rao  3 , Michael G Moore  1 , D Gregory Farwell  1 , Arnaud F Bewley  1
Affiliations

Association of Adjuvant Radiation Therapy With Survival in Patients With Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck

Brianna N Harris et al. JAMA Otolaryngol Head Neck Surg. .

Erratum in

  • Labels Reversed in Figure 1.
    [No authors listed] [No authors listed] JAMA Otolaryngol Head Neck Surg. 2019 Feb 1;145(2):196. doi: 10.1001/jamaoto.2018.4497. JAMA Otolaryngol Head Neck Surg. 2019. PMID: 30789635 Free PMC article. No abstract available.

Abstract

Importance: Cutaneous squamous cell carcinoma (CSCC) is one of the most common malignant tumors worldwide. There is conflicting evidence regarding the indications for and benefits of adjuvant radiation therapy for advanced CSCC tumors of the head and neck.

Objective: To assess indications for adjuvant radiation therapy in patients with CSCC.

Design, setting, and participants: Retrospective analysis of 349 patients with head and neck CSCC treated with primary resection with or without adjuvant radiation therapy at 2 tertiary referral centers from January 1, 2008, to June 30, 2016.

Main outcomes and measures: Data were compared between treatment groups with a χ2 analysis. Disease-free survival (DFS) and overall survival (OS) were analyzed using a Kaplan-Meier survival analysis with log-rank test and a Cox proportional hazards multivariate regression.

Results: A total of 349 patients had tumors that met the inclusion criteria (mean [SD] age, 70 [12] years; age range, 32-94 years; 302 [86.5%] male), and 191 (54.7%) received adjuvant radiation therapy. The 5-year Kaplan-Meier estimates were 59.4% for DFS and 47.4% for OS. Patients with larger, regionally metastatic, poorly differentiated tumors with perineural invasion (PNI) and younger immunosuppressed patients were more likely to receive adjuvant radiation therapy. On Cox proportional hazards multivariate regression, patients with periorbital tumors (hazard ratio [HR], 2.48; 95% CI, 1.00-6.16), PNI (HR, 1.90; 95% CI, 1.12-3.19), or N2 or greater nodal disease (HR, 2.16; 95% CI, 1.13-4.16) had lower DFS. Immunosuppressed patients (HR, 2.17; 95% CI, 1.12-4.17) and those with N2 or greater nodal disease (HR, 2.43; 95% CI, 1.42-4.17) had lower OS. Adjuvant radiation therapy was associated with improved OS for the entire cohort (HR, 0.59; 95% CI, 0.38-0.90). In a subset analysis of tumors with PNI, adjuvant radiation therapy was associated with improved DFS (HR, 0.47; 95% CI, 0.23-0.93) and OS (HR, 0.44; 95% CI, 0.24-0.86). Adjuvant radiation therapy was also associated with improved DFS (HR, 0.36; 95% CI, 0.15-0.84) and OS (HR, 0.30; 95% CI, 0.15-0.61) in patients with regional disease.

Conclusions and relevance: Among patients with advanced CSCC, receipt of adjuvant radiation therapy was associated with improved survival in those with PNI and regional disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Moore reports being a faculty member for AO North America. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Comparison of Surgery vs Surgery Plus Adjuvant Radiation Therapy for the Entire Cohort
Figure 2.
Figure 2.. Subset Analysis of Patients With Perineural Invasion (PNI) and Regional Disease
See this image and copyright information in PMC

References

    1. Rogers HW, Weinstock MA, Harris AR, et al. . Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-287. doi:10.1001/archdermatol.2010.19 - DOI - PubMed
    1. Christenson LJ, Borrowman TA, Vachon CM, et al. . Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005;294(6):681-690. doi:10.1001/jama.294.6.681 - DOI - PubMed
    1. Terra JB, Gaster MB, Halmos GB, et al. . Local control of 151 head and neck cutaneous squamous cell carcinoma after radiation therapy: a retrospective study on efficacy and prognostic factors. Clin Otolaryngol. 2017;42(4):851-855. doi:10.1111/coa.12707 - DOI - PubMed
    1. Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541-547. doi:10.1001/jamadermatol.2013.2139 - DOI - PubMed
    1. Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. . Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system. JAMA Dermatol. 2013;149(4):402-410. doi:10.1001/jamadermatol.2013.2456 - DOI - PubMed

MeSH terms